Scientists engineer drug delivery device that treats glaucoma directly inside the eye

November 23, 2017 by Levi Gadye, Phd, University of California, San Francisco
Scientists engineer drug delivery device that treats glaucoma directly inside the eye
The tiny implant will dissolve, releasing the drug. Credit: Jean Kim/Desai Lab

Glaucoma, which affects over 60 million people worldwide, can seem easy to treat: medicated eye drops can be used to ease the buildup of fluid in the eye that underlies the condition. If glaucoma is caught early, eye drops can prevent irreversible blindness.

But prescription eye drops aren't the perfect solution for glaucoma. Many elderly patients who suffer from glaucoma struggle to take their on time, which is required up to three times a day. And even when patients comply with this intensive eye drop schedule, much of the medication drains into the patient's blood, missing its target inside the eye.

Those problems could be part of the past, thanks to a developed in the lab of Tejal Desai, PhD. The tiny implant promises to simplify how glaucoma drugs are administered, making life easier for aging patients.

Desai, who is chair of the Department of Bioengineering and Therapeutic Sciences, a joint department of the UCSF Schools of Pharmacy and Medicine, recently reported her lab's success using the implant to reduce in animals in the Journal of Controlled Release. The paper's first author, Jean Kim, is a PhD student in the Desai Lab.

Drug implant dissolves to treat glaucoma

Recognizing the need for a delivery method that removes the fuss for patients, the researchers toyed with degradable materials that would slowly release the medication while dissolving in the eye. They settled on a "sandwich" of biodegradable films surrounding an anti- drug. Using this design, "we can load enough drug in the tiny device to last over six months," says Desai.

The researchers implanted the drug-releasing devices and measured eye pressure on a weekly basis for 24 weeks. Beyond some rare and minor complications, the device successfully reduced eye pressure in the animals for the duration of the study.

"While there have been important advances in eye drop formulations, our device substantially reduces the burden of patient compliance in a safe and effective way," Desai says.

Desai is hopeful that her lab's device will soon improve outcomes for . "Next steps will involve scaling up, developing device fabrication procedures that comply with current good manufacturing practices, and testing the device in larger animals, before moving on to clinical trials," she says.

Explore further: XEN-45 implant effective in uncontrolled uveitic glaucoma

More information: Jean Kim et al. Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent, Journal of Controlled Release (2017). DOI: 10.1016/j.jconrel.2017.11.008

Related Stories

XEN-45 implant effective in uncontrolled uveitic glaucoma

October 29, 2017
(HealthDay)—For medically uncontrolled uveitic glaucoma, the XEN-45 implant is effective, reducing the need for further surgery, according to a study published online Oct. 20 in Clinical & Experimental Ophthalmology.

Timed-release glaucoma drug insert shows promise as alternative to daily drops

May 5, 2016
A new device that slowly releases eye medication may one day be a promising option for the many glaucoma patients who struggle with administering their own daily prescription eye drops. New research shows a medicated silicone ...

Stent surgery could benefit select glaucoma patients

August 1, 2017
(HealthDay)—Stent surgery using a 6-mm-long stent made of gelatin material seems promising for patients with glaucoma, according to a report from the University of Michigan.

Clinical study success for novel contact lens device aimed to improve glaucoma treatment

October 19, 2017
A novel contact lens device developed by University of Liverpool engineers to improve the treatment of glaucoma has been found to reliably track pressure changes in the eye and be wearable by people who took part in its first ...

Coming soon: Glaucoma self-care, from home?

September 23, 2017
(HealthDay)—For many glaucoma patients, repeat trips to a doctor's office to check on their eyes can be a real pain.

ECP, second drainage device effective in refractory glaucoma

September 1, 2016
(HealthDay)—For patients with refractory glaucoma with failed initial tube shunt, both endoscopic cyclophotocoagulation (ECP) and implantation of a second glaucoma drainage device (GDD-2) are effective as second surgeries, ...

Recommended for you

Widespread errors in 'proofreading' cause inherited blindness

October 12, 2018
Mistakes in "proofreading" the genetic code of retinal cells is the cause of a form of inherited blindness, retinitis pigmentosa (RP) caused by mutations in splicing factors.

Gene therapy breakthrough in treating rare form of blindness

October 9, 2018
Positive results of the world's first gene therapy trial for a genetic cause of blindness known as choroideremia have been reported in Nature Medicine.

Gene changes driving myopia reveal new focus for drug development

October 9, 2018
Myopia (nearsightedness) and hyperopia (farsightedness) develop through different molecular pathways, according to a new study publishing October 9 in the open-access journal PLOS Biology by Andrei Tkatchenko of Columbia ...

Dynamin-binding protein linked to congenital cataracts

October 4, 2018
Cataracts, a condition in which the eyes' natural lenses get clouded, are the most common cause of vision loss in older people and can be corrected by routine surgery. But congenital cataracts, which occur in infants and ...

Eye discovery to pave way for more successful corneal transplants

October 1, 2018
A team of eye specialists at The University of Nottingham has made another novel discovery that could help to improve the success of corneal transplants for patients whose sight has been affected by disease.

New study confirms Mediterranean diet prevents a leading cause of blindness

October 1, 2018
Evidence is mounting that a poor diet plays an important role in the development of age-related macular degeneration (AMD), a leading cause of blindness in the United States. A large collaboration of researchers from the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.